KURA ONCOLOGY, INC. Accrued Liabilities and Other Liabilities
KURA ONCOLOGY, INC. (KURA) had Accrued Liabilities and Other Liabilities of $54.81 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Payables and Accruals
us-gaap:AccruedLiabilitiesAndOtherLiabilities · last filed 2026-08-12
- 2026-06-30: Accrued Liabilities and Other Liabilities $54.81M.
- 2026-03-31: Accrued Liabilities and Other Liabilities $45.47M.
- 2025-12-31: Accrued Liabilities and Other Liabilities $61.70M.
- 2024-12-31: Accrued Liabilities and Other Liabilities $48.48M.
| Period end | Accrued Liabilities and Other Liabilities |
|---|---|
| 2026-06-30 | $54.81M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $45.47M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $61.70M 10-Q · filed 2026-08-12 |
| 2024-12-31 | $48.48M 10-K · filed 2026-03-05 |
| 2015-12-31 | $1.93M 10-K · filed 2016-03-17 |
| 2014-12-31 | $581.00K 10-K · filed 2016-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |